Humana Inc (HUM) Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC decreased its position in shares of Humana Inc (NYSE:HUM) by 45.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,590 shares of the insurance provider’s stock after selling 5,580 shares during the period. Sterling Capital Management LLC’s holdings in Humana were worth $1,961,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Humana by 12.7% during the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after buying an additional 1,374,030 shares during the last quarter. BlackRock Inc. raised its position in shares of Humana by 1.7% during the first quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock valued at $3,276,068,000 after buying an additional 198,588 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Humana by 0.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,564,251 shares of the insurance provider’s stock valued at $420,503,000 after buying an additional 11,915 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Humana by 7.6% during the second quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after buying an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Humana by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 768,245 shares of the insurance provider’s stock valued at $228,653,000 after buying an additional 26,303 shares during the last quarter. 93.00% of the stock is owned by hedge funds and other institutional investors.

NYSE HUM opened at $337.24 on Friday. The stock has a market capitalization of $45.68 billion, a P/E ratio of 28.80, a price-to-earnings-growth ratio of 1.65 and a beta of 0.96. Humana Inc has a twelve month low of $231.90 and a twelve month high of $339.88. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.79 by $0.17. The business had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter in the previous year, the firm posted $3.49 earnings per share. research analysts anticipate that Humana Inc will post 14.18 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be paid a $0.50 dividend. The ex-dividend date is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.59%. Humana’s payout ratio is currently 17.08%.

A number of research analysts have recently commented on HUM shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $355.00 price objective on shares of Humana in a research report on Thursday, August 2nd. Bank of America upped their price objective on shares of Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Jefferies Financial Group upped their price objective on shares of Humana from $356.00 to $372.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Finally, Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $326.00 price objective for the company in a research report on Monday, May 21st. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana currently has a consensus rating of “Buy” and a consensus target price of $331.11.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Cynthia H. Zipperle sold 4,886 shares of the company’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $321.89, for a total transaction of $1,572,754.54. The disclosure for this sale can be found here. In the last three months, insiders sold 51,752 shares of company stock worth $16,581,234. 0.60% of the stock is currently owned by insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply